JP5871921B2 - ヘスペレチンの新規使用 - Google Patents
ヘスペレチンの新規使用 Download PDFInfo
- Publication number
- JP5871921B2 JP5871921B2 JP2013519943A JP2013519943A JP5871921B2 JP 5871921 B2 JP5871921 B2 JP 5871921B2 JP 2013519943 A JP2013519943 A JP 2013519943A JP 2013519943 A JP2013519943 A JP 2013519943A JP 5871921 B2 JP5871921 B2 JP 5871921B2
- Authority
- JP
- Japan
- Prior art keywords
- hesperetin
- composition
- skin microcirculation
- skin
- microcirculation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 title claims description 106
- AIONOLUJZLIMTK-AWEZNQCLSA-N hesperetin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-AWEZNQCLSA-N 0.000 title claims description 106
- AIONOLUJZLIMTK-UHFFFAOYSA-N hesperetin Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(O)=CC(O)=C2C(=O)C1 AIONOLUJZLIMTK-UHFFFAOYSA-N 0.000 title claims description 106
- 235000010209 hesperetin Nutrition 0.000 title claims description 106
- 229960001587 hesperetin Drugs 0.000 title claims description 106
- FTODBIPDTXRIGS-UHFFFAOYSA-N homoeriodictyol Natural products C1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 FTODBIPDTXRIGS-UHFFFAOYSA-N 0.000 title claims description 106
- 230000004089 microcirculation Effects 0.000 claims description 75
- 239000000203 mixture Substances 0.000 claims description 65
- 239000000419 plant extract Substances 0.000 claims description 30
- 239000000284 extract Substances 0.000 claims description 28
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 235000020971 citrus fruits Nutrition 0.000 claims description 14
- 210000000744 eyelid Anatomy 0.000 claims description 14
- 241000207199 Citrus Species 0.000 claims description 12
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 5
- 238000011200 topical administration Methods 0.000 claims description 5
- -1 dimethylsiloxane Chemical class 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims 4
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims 4
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims 2
- RMTFNDVZYPHUEF-XZBKPIIZSA-N 3-O-methyl-D-glucose Chemical group O=C[C@H](O)[C@@H](OC)[C@H](O)[C@H](O)CO RMTFNDVZYPHUEF-XZBKPIIZSA-N 0.000 claims 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
- 150000007942 carboxylates Chemical class 0.000 claims 2
- 229960000541 cetyl alcohol Drugs 0.000 claims 2
- 235000011187 glycerol Nutrition 0.000 claims 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 2
- 235000010445 lecithin Nutrition 0.000 claims 2
- 239000000787 lecithin Substances 0.000 claims 2
- 229940067606 lecithin Drugs 0.000 claims 2
- 229920001285 xanthan gum Polymers 0.000 claims 2
- 239000000230 xanthan gum Substances 0.000 claims 2
- 229940082509 xanthan gum Drugs 0.000 claims 2
- 235000010493 xanthan gum Nutrition 0.000 claims 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 235000019437 butane-1,3-diol Nutrition 0.000 claims 1
- 239000004310 lactic acid Substances 0.000 claims 1
- 235000014655 lactic acid Nutrition 0.000 claims 1
- 239000003755 preservative agent Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 230000037303 wrinkles Effects 0.000 description 19
- 238000009472 formulation Methods 0.000 description 16
- 230000000694 effects Effects 0.000 description 15
- 239000002537 cosmetic Substances 0.000 description 13
- 230000001717 pathogenic effect Effects 0.000 description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 description 9
- 230000017531 blood circulation Effects 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 235000013399 edible fruits Nutrition 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 230000000699 topical effect Effects 0.000 description 6
- 229940025703 topical product Drugs 0.000 description 5
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010018852 Haematoma Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 210000004088 microvessel Anatomy 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000675108 Citrus tangerina Species 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010016717 Fistula Diseases 0.000 description 1
- 244000034644 Galium mollugo Species 0.000 description 1
- 241000246169 Genista Species 0.000 description 1
- 235000011201 Ginkgo Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 239000009429 Ginkgo biloba extract Substances 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000131316 Panax pseudoginseng Species 0.000 description 1
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 1
- 235000003140 Panax quinquefolius Nutrition 0.000 description 1
- QMQIQBOGXYYATH-IDABPMKMSA-N Ruscogenin Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)[C@H](O)C[C@H](O)CC4=CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@@H](C)CO1 QMQIQBOGXYYATH-IDABPMKMSA-N 0.000 description 1
- BSUPFYRQXCQGLJ-UHFFFAOYSA-N Ruscogenin Natural products CC1CCC2(OC1)OC3C(O)C4C5CC=C6CC(O)CC(O)C6(C)C5CCC4(C)C3C2C BSUPFYRQXCQGLJ-UHFFFAOYSA-N 0.000 description 1
- 240000000353 Ruscus aculeatus Species 0.000 description 1
- 235000003500 Ruscus aculeatus Nutrition 0.000 description 1
- ZONYXWQDUYMKFB-UHFFFAOYSA-N SJ000286395 Natural products O1C2=CC=CC=C2C(=O)CC1C1=CC=CC=C1 ZONYXWQDUYMKFB-UHFFFAOYSA-N 0.000 description 1
- 241000304195 Salvia miltiorrhiza Species 0.000 description 1
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000036983 biotransformation Effects 0.000 description 1
- 239000012490 blank solution Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- QMQIQBOGXYYATH-UHFFFAOYSA-N epiruscogenin Natural products CC1C(C2(CCC3C4(C)C(O)CC(O)CC4=CCC3C2C2)C)C2OC11CCC(C)CO1 QMQIQBOGXYYATH-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003890 fistula Effects 0.000 description 1
- 229930003949 flavanone Natural products 0.000 description 1
- 150000002207 flavanone derivatives Chemical class 0.000 description 1
- 235000011981 flavanones Nutrition 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 235000020686 ginkgo biloba extract Nutrition 0.000 description 1
- 229940068052 ginkgo biloba extract Drugs 0.000 description 1
- 235000008434 ginseng Nutrition 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000011176 pooling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940109990 ruscogenin Drugs 0.000 description 1
- 229940119485 safflower extract Drugs 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 230000036559 skin health Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000012353 t test Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000000264 venule Anatomy 0.000 description 1
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000000216 zygoma Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Description
微小循環を促進するための実験方法:体重3.0kg〜3.5kgの雄のアナウサギ(Oryctolagus cuniculus)を使用した。アナウサギの背中の毛を剃った後、血流を試験するために、ウサギの毛のない皮膚上に10点、すなわち右側及び左側それぞれ5点ずつマーカーペンを用いて印を付け、点を付けるときは大動脈を避けた。サンプルを塗布する前に、それぞれの実験群のウサギの10点での血流の基本値を、レーザードップラー血流測定によって決定した。それぞれの群のウサギに対し、左側の背中にブランク溶液を塗布し、右側の背中にヘスペレチン含有溶液を塗布した(3つの動物群に関して、溶液の濃度はそれぞれ、0.5%、1%及び2%であり、各動物で0.1mlであった)。それぞれの濃度で3匹のウサギを並行して使用した。2%溶液を塗布により投与した群で使用される容量と比較して100倍の容量で、同じような方法によって2%溶液を経口投与した。投与後、24時間、レーザードップラー血流測定により同じ点で1時間ごとに血流値を決定し、血流の変動指数を計算し、ウサギの背中の血液に対するヘスペレチンの効果を評価した。血流の変動指数が高ければ、微小循環を促進する効果がより良好であることを示す。実験結果をSPSS11.5ソフトウェアによって統計的に分析し、t検定を測定データに適用して、実験結果を評価した。P<0.1の場合に、データが統計的に有意であるとみなすことができる。表1の結果では、24時間試験でP<0.1の時点を全て列挙した。
方法:両眼での2つの配合物の8週比較実験を本研究で使用した。
一対比較1:組成物1(基本配合物)対組成物2(基本配合物+0.5%ヘスペレチン)
一対比較2:組成物1(基本配合物)対組成物3(基本配合物+2%ヘスペレチン)
一対比較3:組成物1(基本配合物)対組成物4(基本配合物+10%ヘスペレチン抽出物)
Claims (8)
- (1)有効量のヘスペレチン又はヘスペレチン含有植物抽出物と、(2)生理学的に許容可能な賦形剤を含む組成物であって、
該ヘスペレチン含有植物抽出物が、ミカン科の柑橘類植物の果皮から、又はトゲナシムグラの地上部から抽出することにより得られる抽出物であり、かつ、50%以上の量でヘスペレチンを含有する抽出物であり、
該賦形剤はセスキステアリン酸メチルグルコース、ジメチルシロキサン、セタノール/オクタデカノール、カルボン酸ジカプリル、オクタン酸プロピリルヘプチル、レシチン、キサンタンゴム、1,3−ブタンジオール、EDTA−2Na、グリセリン及びトリエタノールアミンからなり、
該ヘスペレチン又は該ヘスペレチン含有植物抽出物が、ヘスペレチンの重量により計算して、該組成物の総重量の0.2wt%〜2wt%を占める、組成物。 - (1)有効量のヘスペレチン又はヘスペレチン含有植物抽出物と、(2)生理学的に許容可能な賦形剤からなる組成物であって、
該ヘスペレチン含有植物抽出物が、ミカン科の柑橘類植物の果皮から、又はトゲナシムグラの地上部から抽出することにより得られる抽出物であり、かつ、50%以上の量でヘスペレチンを含有する抽出物であり、
該賦形剤は、組成物の総重量の1.2%のセスキステアリン酸メチルグルコース、1.0%のジメチルシロキサン、3%のセタノール/オクタデカノール、4%のカルボン酸ジカプリル、2%のオクタン酸プロピリルヘプチル、2.5%のレシチン、0.3%のキサンタンゴム、4%の1,3−ブタンジオール、0.2%のEDTA−2Na、2.0%のグリセリン、2%のトリエタノールアミン、乳酸、保存料及び残部水からなり、
該ヘスペレチン又は該ヘスペレチン含有植物抽出物が、ヘスペレチンの重量により計算して、該組成物の総重量の0.2wt%〜2wt%を占める、請求項1に記載の組成物。 - 局所投与用の製品である、請求項1又は2に記載の組成物。
- 皮膚微小循環を改善する及び/又は促進する、又は皮膚微小循環の不良に関連する疾患若しくは病態を排除する及び/又は緩和する方法であって、有効量の請求項1〜3のいずれかに記載の組成物を、それを必要とする、ヒトを除く被験者に投与することを含む、方法。
- 皮膚微小循環を改善する及び/又は促進する、又は皮膚微小循環の不良に関連する疾患若しくは病態を排除する及び/又は緩和する製品の製造における請求項1〜3のいずれかに記載の組成物の使用。
- 前記皮膚微小循環が眼の皮膚微小循環である、請求項5に記載の使用。
- 前記皮膚微小循環の不良に関連する疾患又は病態が、眼の皮膚微小循環の不良に関連する疾患又は病態である、請求項5に記載の使用。
- 前記眼の皮膚微小循環の不良に関連する疾患又は病態が眼の下の隈である、請求項5に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201010231389.2 | 2010-07-20 | ||
CN201010231389.2A CN102266320B (zh) | 2010-07-20 | 2010-07-20 | 橙皮素的新用途 |
PCT/CN2011/075765 WO2012010022A1 (zh) | 2010-07-20 | 2011-06-15 | 橙皮素的新用途 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2013536169A JP2013536169A (ja) | 2013-09-19 |
JP2013536169A5 JP2013536169A5 (ja) | 2015-09-03 |
JP5871921B2 true JP5871921B2 (ja) | 2016-03-01 |
Family
ID=45048905
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013519943A Active JP5871921B2 (ja) | 2010-07-20 | 2011-06-15 | ヘスペレチンの新規使用 |
Country Status (7)
Country | Link |
---|---|
US (1) | US9351952B2 (ja) |
EP (1) | EP2596787B1 (ja) |
JP (1) | JP5871921B2 (ja) |
KR (1) | KR101817514B1 (ja) |
CN (1) | CN102266320B (ja) |
HK (1) | HK1162953A1 (ja) |
WO (1) | WO2012010022A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101817187B1 (ko) | 2011-11-25 | 2018-01-10 | 내처럴 메디슨 인스티튜트 오브 제지앙 양솅탕 컴퍼티 리미티드 | 네오헤스페리딘의 신규의 용도 |
CN104188819B (zh) * | 2014-09-25 | 2016-08-03 | 山西医科大学 | 一种透明质酸分散的橙皮素纳米爽肤水及其制备方法 |
WO2017038951A1 (ja) * | 2015-09-02 | 2017-03-09 | 株式会社林原 | 黄ぐすみ低減用皮膚外用剤 |
CN111888371A (zh) * | 2020-08-07 | 2020-11-06 | 广东工业大学 | 一种糖基化橙皮素化合物在制备缓解痛经制品中的应用 |
CN115053963A (zh) * | 2022-06-28 | 2022-09-16 | 仙乐健康科技股份有限公司 | 一种提升体温和促进体表微循环的组合物 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU6666594A (en) * | 1993-04-20 | 1994-11-08 | Procter & Gamble Company, The | Methods of using hesperetin for sebum control and treatment of acne |
FR2778663B1 (fr) * | 1998-05-15 | 2001-05-18 | Coletica | Nouveaux esters de flavonoides,leur utilisation en cosmetique, dermopharmacie, en pharmacie et en agro-alimentaire |
JP2001072564A (ja) * | 1999-09-08 | 2001-03-21 | Kanebo Ltd | くま改善剤 |
US6607735B2 (en) * | 2000-12-21 | 2003-08-19 | Johnson & Johnson Consumer Companies, Inc. | Method for reducing the appearance of dark circles under the eyes |
WO2003053336A2 (en) * | 2001-12-19 | 2003-07-03 | The Quigley Corporation | Methods for the treatment of peripheral neural and vascular ailments |
FR2834639A1 (fr) * | 2002-01-11 | 2003-07-18 | Medix Lab | Composition comprenant en association au moins un flavonoide et au moins une huile vegetale, son utilisation comme agent dermatologique ou dermatocosmetique |
FR2836042B1 (fr) * | 2002-02-15 | 2004-04-02 | Sederma Sa | Compositions cosmetiques ou dermopharmaceutiques pour diminuer les poches et cernes sous les yeux |
US20080008673A1 (en) * | 2006-07-03 | 2008-01-10 | Claudie Willemin | Compositions comprising at least one C-glycoside derivative |
FR2919501B1 (fr) * | 2007-08-02 | 2010-12-31 | Oreal | Utilisation d'hesperidine ou de l'un de ses derives pour la prevention et/ou le traitement des peaux relachees |
WO2009116450A1 (ja) * | 2008-03-17 | 2009-09-24 | 株式会社林原生物化学研究所 | エラスターゼ活性阻害剤 |
EP2262469A4 (en) | 2008-04-15 | 2013-12-04 | Immanence Integrale Dermo Correction Inc | SKIN CARE COMPOSITIONS AND METHODS OF USE |
FR2933608B1 (fr) * | 2008-07-11 | 2014-01-10 | Lvmh Rech | Nouvelle utilisation d'un extrait de grande mauve agent hydratant, et composition cosmetique le contenant. |
JP5203084B2 (ja) * | 2008-07-30 | 2013-06-05 | 江崎グリコ株式会社 | 分散ヘスペレチン |
-
2010
- 2010-07-20 CN CN201010231389.2A patent/CN102266320B/zh active Active
-
2011
- 2011-06-15 WO PCT/CN2011/075765 patent/WO2012010022A1/zh active Application Filing
- 2011-06-15 JP JP2013519943A patent/JP5871921B2/ja active Active
- 2011-06-15 KR KR1020137003693A patent/KR101817514B1/ko active IP Right Grant
- 2011-06-15 EP EP11809210.5A patent/EP2596787B1/en active Active
- 2011-06-15 US US13/810,828 patent/US9351952B2/en active Active
-
2012
- 2012-04-12 HK HK12103639.7A patent/HK1162953A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
JP2013536169A (ja) | 2013-09-19 |
US20130131160A1 (en) | 2013-05-23 |
CN102266320A (zh) | 2011-12-07 |
EP2596787A4 (en) | 2013-12-25 |
KR20130038925A (ko) | 2013-04-18 |
KR101817514B1 (ko) | 2018-01-11 |
EP2596787B1 (en) | 2015-11-25 |
WO2012010022A1 (zh) | 2012-01-26 |
CN102266320B (zh) | 2015-06-17 |
EP2596787A1 (en) | 2013-05-29 |
US9351952B2 (en) | 2016-05-31 |
HK1162953A1 (en) | 2012-09-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11285093B2 (en) | Cosmetic uses of swertiamarin | |
US5679358A (en) | Formulations containing esculoside and the use thereof in the pharmaceutical and cosmetic fields | |
KR101908978B1 (ko) | 스트레스 완화 및 피로 회복 효과를 갖는 향료 조성물 및 이를 함유하는 화장료 조성물 | |
JP5871921B2 (ja) | ヘスペレチンの新規使用 | |
JP2010059161A (ja) | 精油の混合物を含む化粧用又は皮膚科用組成物、及び特に敏感肌又は感作肌のケアのためのその使用 | |
JP2006514957A (ja) | 顔面のしわを治療するスベリヒユの使用 | |
US20150118334A1 (en) | Topical compositions for the treatment of chronic inflammatory skin disease | |
EP2306999B1 (en) | Compositions for treating rosacea comprising chitosan and a dicarboxylic acid amide | |
CN111821228A (zh) | 一种祛黄抗皮肤光老化的组合物及其应用 | |
US11260011B2 (en) | Use of neohesperidin | |
CN107115383B (zh) | 具有防治皮肤干燥综合征功效的皮肤养护/治疗组合物 | |
TWI421098B (zh) | New use of new hesperidin | |
KR20230143023A (ko) | 시지지움 포르모슘 추출물을 유효성분으로 포함하는 피부 개선용 조성물 | |
TWI491404B (zh) | New use of hesperetin | |
DE202006019185U1 (de) | Feuchtigkeitsspendendes, wasserhaltiges Sanddorn-Hautpflegepräparat | |
AU2022236886A1 (en) | Methods of using compositions comprising an iceland moss extract | |
PL244324B1 (pl) | Krem pod oczy typu olej w wodzie | |
BR102019009943A2 (pt) | formulação cosmética para cuidados da saúde dos pés e uso da mesma | |
DE202006018519U1 (de) | Feuchtigkeitsspendende wasserhaltige Sanddorn-Hautpflegepräparate (Emulsionen) | |
TW200900089A (en) | Cosmetic preparations designed to reduce unsightly cellulite | |
JP2002293728A (ja) | 収斂化粧料 | |
RO129526A2 (ro) | Cremă destinată eliminării vitiligo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20140221 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150224 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150522 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20150624 |
|
A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20150707 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160105 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160112 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5871921 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |